)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Marinomed Biotech
Marinomed Biotech (MARI) investor relations material
Marinomed Biotech has been delisted
Marinomed Biotech Austrian Select Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Austrian Select Conference summary23 Apr, 2026
Leadership and Ownership
Leadership team includes experienced biotech entrepreneurs and industry veterans, with significant management and founder ownership and a large free float of 73.5%.
Long-term shareholders from the Middle East have supported the company since 2006.
Strategic Assets and Partnering
Budesolv and Tacrosolv, two late-stage assets, have completed successful clinical trials and are in advanced partnering discussions with Big Pharma, targeting multi-billion dollar allergy and ophthalmology markets.
Budesolv is at term sheet stage, Tacrosolv at LOI stage, with Budesolv registration ongoing in Switzerland and launches planned post-approval.
Tacrosolv development continues through strategic partnerships, with phase 3 trials and compounding business expansion targeted for 2027-2028.
Recent capital increase strengthens negotiation position and supports milestone achievement.
All non-external funded projects are on hold to focus resources on top commercialization opportunities.
Technology and Business Model
Proprietary Marinosolv technology enables solubilization of insoluble drugs, with patents and clinical validation.
Business model includes in-house projects, client-sponsored Solv4U services, and new component supply for compounding pharmacies.
Revenue streams include upfront payments, milestones, royalties, service fees, and supply to compounding pharmacies.
Strategic focus on partnering, cost efficiency, and ramping up compounding business to optimize cash flow and profitability.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Marinomed Biotech
- Revenue fell to €9.18m; liquidity hinges on licensing and commercialization.MARI
H2 2023 - Strong profit rebound in 2025 after restructuring, but future hinges on milestone payments.MARIH2 2025
- Late-stage assets with disruptive technology are nearing commercialization through global partnerships.MARIGBC International Investment Forum
- H1 2025 saw strong profit and liquidity gains from asset sales and restructuring, with focus shifting to Marinosolv.MARIH1 2025
- Disruptive solubilization technology, financial turnaround, and global expansion drive future growth.MARIHealth Care Conference
- Restructuring and Carragelose sale refocus Marinomed on Marinosolv and future profitability.MARIH2 2024
- Revenue halved and insolvency triggered a major restructuring, with future hinging on Marinosolv.MARIH1 2024
Marinomed Biotech
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Marinomed Biotech AG is an Austrian biotechnology company specializing in antiviral and immunology products. The company develops therapies based on proprietary technology platforms for treating respiratory and ocular diseases. It focuses on both prescription and over-the-counter formulations with applications in global healthcare markets. The company is headquartered in Korneuburg, Austria, and its shares are listed on the VSE.